Highlights Oragenics, Inc.

Equities

OGEN

US6840235005

Delayed Nyse Other stock markets 01:30:00 17/05/2024 am IST			5-day change	1st Jan Change
1.64 ^USD	+0.12%		+18.84%	-70.85%

16/05	Sector Update: Health Care Stocks Ease Thursday Afternoon	MT
16/05	Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Ease Thursday Afternoon	16/05	MT
Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise	16/05	MT
Oragenics, Inc. Announces Partnership with Avance Clinical to Conduct Phase II Clinical Trial in Australia	07/05	CI
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	05/03	CI
Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion	05/02	CI
Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	28/12	CI
Oragenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Oragenics Signs Cash, Share Deal to Acquire Odyssey Health's Neurological Drug Technology Pipeline	05/23/05	MT
Oragenics, Inc. entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	05/23/05	CI
Oragenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	12/23/12	CI
Oragenics to Develop Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate	06/23/06	MT
Oragenics, Inc. Announces the Award of Grant from CQDM for the Collaborative Development of a Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate	06/23/06	CI
Oragenics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13	CI
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	18/23/18	CI
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE	14/23/14	CI
Oragenics, Inc. Enters into an Exclusive Global License Agreement with Inspirevax Inc	01/23/01	CI
Oragenics, Inc. Enters into an Exclusive Global License Agreement with Inspirevax Inc to Develop Intranasal Covid Vaccine Candidate	01/23/01	CI
Oragenics Regains Compliance with NYSE American's Continued Listing Standards	03/23/03	MT
Reverse Split: 1 of 60	23/23/23	FA

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oragenics, Inc.

Equities

OGEN

US6840235005

Highlights

Filters